12 January 2016
A new study has demonstrated the potential anti-cancer benefits of diclofenac, a common painkiller.
The Repurposing Drugs in Oncology (ReDO) project - an international collaboration between Belgium's Anticancer Fund and the US-based GlobalCures - has indicated that this affordable therapy offers untapped potential in the treatment of cancer.
According to research published in ecancermedicalscience, the widely used nonsteroidal anti-inflammatory drug could be taken in combination with other treatments, such as chemotherapy and radiotherapy, to improve their effectiveness.
It offers multiple mechanisms of action, particularly with relation to angiogenesis and the immune system, and offers the potential to cut the risk of postsurgical distant metastases.
This comes as part of ReDO's wider efforts to learn more about the exact functionality of everyday drugs in order to see how they might offer broader applications.
Study author Dr Pan Pantziarka, member of the ReDO project and the Anticancer Fund, said: "The more we learn, the more we can see that these drugs are multi-targeted agents with interesting and useful effects on multiple pathways of interest in oncology."
Posted by Jeanette Royston
Health News is provided by Axonn Media in collaboration with Spire Healthcare. Please note that all copy above is ©Axonn Media and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.